CHARACTERISTICS OF BLOOD CELL COUNT TEST AND BASIC COAGULATION IN LIVER CANCER PATIENTS

Thị Thu Trang Đinh, Thị Thuỷ Nguyên Trần, Thu Soan Hoàng, Tiến Thăng Vũ, Thị Phương Lan Vi

Main Article Content

Abstract

Objective: Describe blood cell count test indexes and basic coagulation test indexes (PT, APTT, Fbg) in liver cancer patients. Method: cross-sectional description of blood cell count test and basic coagulation indices of liver cancer patients at the Hematology and Blood Transfusion Center of Thai Nguyen Central Hospital since 6/2022 to 5/2023. Results: the patient's RBC was 4.08±0.89 T/L, HGB was 119.77±28.29 g/L; HCT was 36.60±8.31 L/L; MCV was 89.86±9.33 fL; MCH is 29.40±3.88 pg; MCHC is 326.43±18.45 g/L; RDW is 15.74±3.11%. The rate of anemia accounts for 49.02%, of which mild anemia accounts for 35.29%; Moderate level is 11.76%, severe level is 1.31%, very severe level is 0.65%. The proportion of patients with leukocytosis is 21.57%; Thrombocytosis was 7.8%; Leukopenia was 12.43%; Thrombocytopenia was 32.68%. The proportion of patients with decreased PT% was 57.61%, prolonged PTs was 78.26%, 100% of patients had prolonged PTr. The prolonged APTTs was 2.23% and the prolonged APTTr was 44.44%, the reduced APTTs was 64.44%, and the reduced APTTr was 3.34%, and the increased Fibrinogen was 62.50%. The PLT has a weak negative relationship with the HGB. Conclusion: In liver cancer patients, the majority have changes in basic coagulation indices and indices in peripheral blood cell analysis tests in opposite directions.

Article Details

References

Hoàng V. H., và cs, Nghiên cứu đặc điểm hình ảnh ung thư biểu mô tế bào gan nguyên phát trên cắt lớp vi tính và một số yếu tố liên quan. Tạp Chí Y học Việt Nam, 2023, 527(1).
2. Quang T. và cs, Đặc điểm bệnh nhân ung thư biểu mô tế bào gan tại đơn vị ung thư gan mật và ghép gan-Khoa ngoại gan mật tụy Bệnh viện đại học Y-Dược thành phố Hồ Chí Minh, Tạp Chí Y học Việt Nam, 2021, 504(2).
3. Fan Z. et al, Predictive Value of Platelet-Related Measures in Patients with Hepatocellular Carcinoma, Technol Cancer Res Treat, 2022, doi: 10.1177/15330338211064414.
4. Pavlovic N, et al, Platelets as Key Factors in Hepatocellular Carcinoma. Cancers (Basel), 2019, 11(7):1022.
5. Wang X. P. et al, A retrospective discussion of the prognostic value of combining prothrombin time (PT) and fibrinogen (Fbg) in patients with Hepatocellular carcinoma, J Cancer, 2017, 8 (11), 2079-2087.
6. Yanjun S. et al, Early Prediction of Objective Response of Fibrinogen in a Real-World Cohort of Hepatocellular Carcinoma Cases Treated by Programmed Cell Death Receptor-1 and Lenvatinib, OncoTargets and Therapy, 2022, 14, 5019-5026.
7. Zhang X. et al, Elevated serum plasma fibrinogen is associated with advanced tumor stage and poor survival in hepatocellular carcinoma patients. Medicine (Baltimore), 2017, 96 (17):e6694.
8. Zhu Y.W. et al, Routine Hemostasis and Hemogram Parameters: Valuable Assessments for Coagulation Disorder and Chemotherapy in Cancer Patients. Chin Med J (Engl), 2016, 5;129(15):1772-1777.